

VÃ©ronique Avettand-Fenoel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5756500/publications.pdf>

Version: 2024-02-01

148
papers

6,564
citations

66315

42
h-index

71651

76
g-index

157
all docs

157
docs citations

157
times ranked

6996
citing authors

#	ARTICLE	IF	CITATIONS
1	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, 77, 735-739.	1.3	4
2	The Coris BioConcept COVID 19 Ag Respi-Strip, a field experience feedback. Journal of Virological Methods, 2022, 300, 114366.	1.0	2
3	Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. Nature Communications, 2022, 13, 521.	5.8	22
4	Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. EBioMedicine, 2022, 79, 103985.	2.7	10
5	Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial. Journal of Antimicrobial Chemotherapy, 2022, 77, 2506-2515.	1.3	7
6	Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. Leukemia, 2021, 35, 764-776.	3.3	24
7	Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence. Clinical Infectious Diseases, 2021, 73, e4214-e4222.	2.9	4
8	Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 1564-1572.	1.3	2
9	Impact of Early Versus Late Antiretroviral Treatment Initiation on Naive T Lymphocytes in HIV-1-Infected Children and Adolescents – The-ANRS-EP59-CLEAC Study. Frontiers in Immunology, 2021, 12, 662894.	2.2	9
10	Immunoblots may not be effective in confirming the recency of HIV-1 infection. Journal of Virological Methods, 2021, 290, 114074.	1.0	1
11	CXCR3 and CXCR5 are highly expressed in HIV-specific CD8 central memory T cells from infected patients. European Journal of Immunology, 2021, 51, 2040-2050.	1.6	2
12	Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection. Journal of Virology, 2021, 95, e0001621.	1.5	9
13	Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. EClinicalMedicine, 2021, 37, 100963.	3.2	5
14	Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa. Annals of Hematology, 2021, 100, 2813-2824.	0.8	11
15	Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance. HIV Medicine, 2021, 22, 958-964.	1.0	7
16	Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?. Journal of Antimicrobial Chemotherapy, 2020, 75, 183-193.	1.3	8
17	False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers. Clinical Infectious Diseases, 2020, 70, 1754-1757.	2.9	1
18	Genital Human Immunodeficiency Virus RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials. Clinical Infectious Diseases, 2020, 70, 1973-1979.	2.9	3

#	ARTICLE	IF	CITATIONS
19	High rates of antiretroviral coverage and virological suppression in HIV-1-infected children and adolescents. <i>MÃ©decine Et Maladies Infectieuses</i> , 2020, 50, 269-273.	5.1	4
20	Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study. <i>Cell Reports</i> , 2020, 32, 108174.	2.9	12
21	Dominant-negative mutations in human <i>IL6ST</i> underlie hyper-IgE syndrome. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	64
22	Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection. <i>EBioMedicine</i> , 2020, 62, 103129.	2.7	22
23	Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation. <i>Frontiers in Immunology</i> , 2020, 11, 604353.	2.2	9
24	Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV-1 infection: results from a longitudinal study in the French ANRS Primo cohort. <i>Journal of the International AIDS Society</i> , 2020, 23, e25485.	1.2	10
25	Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1324-1331.	1.3	6
26	Arsenic trioxide (As ₂ O ₃) as a maintenance therapy for adult T cell leukemia/lymphoma. <i>Retrovirology</i> , 2020, 17, 5.	0.9	20
27	Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 3462-3476.	2.6	38
28	Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	1.3	1
29	HIV controllers: to treat or not to treat? Is that the right question?. <i>Lancet HIV</i> , the, 2019, 6, e878-e884.	2.1	13
30	Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naïve chronically HIV-infected patients in 2015/2016 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1417-1424.	1.3	12
31	Similar efficacy and safety of dolutegravir between age groups of HIV -infected paediatric and young adult patients aged 5 years and older. <i>HIV Medicine</i> , 2019, 20, 561-566.	1.0	10
32	Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection. <i>EBioMedicine</i> , 2019, 41, 455-464.	2.7	12
33	MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE-TYPE AND IS A THERAPEUTIC TARGET IN ADULT T-CELL LEUKEMIA/LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 271-272.	0.8	0
34	HIV-mediated immune aging in young adults infected perinatally or during childhood. <i>Aids</i> , 2019, 33, 1705-1710.	1.0	19
35	The proportion of CD57+ cells among effector CD8+ T cells is lower in HIV controllers compared with antiretroviral therapy-treated patients. <i>Aids</i> , 2019, 33, 2137-2147.	1.0	1
36	Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 605-613.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Does Changing Antiretroviral Therapy in the First Trimester of Pregnancy for Safety Concerns Have an Impact on Viral Suppression?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 574-584.	0.9	4
38	No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained <scp>BK</scp> virus viremia after kidney transplantation: a single-center experience. <i>Transplant International</i> , 2019, 32, 481-492.	0.8	8
39	Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: Underestimation of some CRF02 strains. <i>Journal of Clinical Virology</i> , 2019, 110, 36-41.	1.6	3
40	Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 1498-1505.	2.9	49
41	Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection. <i>Cell Metabolism</i> , 2019, 29, 611-626.e5.	7.2	124
42	Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 718-721.	1.3	4
43	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1597-1604.	0.4	2
44	Dynamics in HIV DNA levels over time in HIV controllers. <i>Journal of the International AIDS Society</i> , 2019, 22, e25221.	1.2	21
45	Poor palatability of the new ritonavir formulation is a major obstacle to adherence to treatment in young children. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1435-1437.	1.3	1
46	Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. <i>Transplant Infectious Disease</i> , 2018, 20, e12846.	0.7	7
47	Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 1519-1527.	2.9	25
48	Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant. <i>Journal of Clinical Virology</i> , 2018, 99-100, 57-60.	1.6	5
49	What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM. <i>EBioMedicine</i> , 2018, 27, 51-60.	2.7	8
50	Total HIV DNA: a global marker of HIV persistence. <i>Retrovirology</i> , 2018, 15, 30.	0.9	42
51	Predominance of G9P[8] rotavirus strains throughout France, 2014-2017. <i>Clinical Microbiology and Infection</i> , 2018, 24, 660.e1-660.e4.	2.8	17
52	Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3. <i>MBio</i> , 2018, 9, .	1.8	28
53	Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1020-1024.	1.3	1
54	Mass Cytometry Analysis Reveals the Landscape and Dynamics of CD32a+ CD4+ T Cells From Early HIV Infection to Effective cART. <i>Frontiers in Immunology</i> , 2018, 9, 1217.	2.2	22

#	ARTICLE	IF	CITATIONS
55	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. <i>Clinical Infectious Diseases</i> , 2018, 66, 1588-1594.	2.9	15
56	HIV DNA. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 389-394.	1.5	12
57	Prevalence of drug resistance in children recently diagnosed with HIV-1 infection in France (2006â€“17): impact on susceptibility to first-line strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2475-2479.	1.3	7
58	Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw464.	1.3	15
59	Spatiotemporal dynamics of HIV-1 transmission in France (1999â€“2014) and impact of targeted prevention strategies. <i>Retrovirology</i> , 2017, 14, 15.	0.9	59
60	HIV Infection in the Native and Allograft Kidney. <i>Transplantation</i> , 2017, 101, 2003-2008.	0.5	15
61	Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2351-2354.	1.3	7
62	Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies. <i>Journal of Medical Virology</i> , 2017, 89, 2047-2050.	2.5	10
63	A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx064.	0.4	45
64	Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis. <i>Nature Communications</i> , 2017, 8, 15264.	5.8	77
65	HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection. <i>EBioMedicine</i> , 2017, 21, 158-169.	2.7	45
66	High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2681-2683.	1.3	6
67	Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality. <i>Leukemia</i> , 2017, 31, 2532-2535.	3.3	22
68	New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2850-2857.	1.8	14
69	NKG2C ⁺ memory-like NK cells contribute to the control of HIV viremia during primary infection: Optprimâ€“ANRS 147. <i>Clinical and Translational Immunology</i> , 2017, 6, e150.	1.7	42
70	Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir. <i>Aids</i> , 2017, 31, 181-189.	1.0	29
71	Ageing with HIV: do comorbidities and polymedication drive treatment optimization?. <i>HIV Medicine</i> , 2017, 18, 395-401.	1.0	22
72	Gag-Specific CD4 T Cell Proliferation, Plasmacytoid Dendritic Cells, and Ethnicity in Perinatally HIV-1-Infected Youths: The ANRS-EP38-IMMIP Study. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 21-28.	0.5	1

#	ARTICLE	IF	CITATIONS
73	A Mature NK Profile at the Time of HIV Primary Infection Is Associated with an Early Response to cART. <i>Frontiers in Immunology</i> , 2017, 8, 54.	2.2	30
74	Gag-Specific CD8 T-Cell Proliferation Is Associated With Higher Peripheral Blood Levels of Transforming Growth Factor- β and Gut-Homing T Cells in Youths Perinatally Infected With Human Immunodeficiency Virus-1: The ANRS-EP38-IMMIP Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw239.	0.4	0
75	Impact of early cART on HIV blood and semen compartments at the time of primary infection. <i>PLoS ONE</i> , 2017, 12, e0180191.	1.1	25
76	Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. <i>Clinical Microbiology Reviews</i> , 2016, 29, 859-880.	5.7	185
77	Polyfunctional HIV-specific T cells in Post-Treatment Controllers. <i>Aids</i> , 2016, 30, 2299-2302.	1.0	26
78	Sequential treatment with 5-azacitidine and deacetylase inhibitors reactivates HIV-1. <i>EMBO Molecular Medicine</i> , 2016, 8, 117-138.	3.3	73
79	Clinical severity and molecular characteristics of circulating and emerging rotaviruses in young children attending hospital emergency departments in France. <i>Clinical Microbiology and Infection</i> , 2016, 22, 737.e9-737.e15.	2.8	8
80	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. <i>Journal of Virology</i> , 2016, 90, 6148-6158.	1.5	50
81	Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load. <i>HIV Medicine</i> , 2016, 17, 380-384.	1.0	4
82	HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. <i>Lancet HIV</i> , 2016, 3, e49-e54.	2.1	131
83	Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1046-1050.	1.3	59
84	Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 751-761.	1.3	18
85	Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 490-496.	1.3	2
86	Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the leDEA West Africa Collaboration. <i>PLoS ONE</i> , 2015, 10, e0129886.	1.1	21
87	Gag-Specific CD4 and CD8 T-Cell Proliferation in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection Is Associated with Ethnicity. The ANRS-EP38-IMMIP Study. <i>PLoS ONE</i> , 2015, 10, e0144706.	1.1	2
88	Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection. <i>PLoS Pathogens</i> , 2015, 11, e1005153.	2.1	191
89	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1507-1512.	1.3	52
90	Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 387-396.	4.6	67

#	ARTICLE	IF	CITATIONS
91	Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1921-1923.	1.3	21
92	Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2108-2120.	1.3	92
93	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-2012: impact on susceptibility to first-line strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2084-2089.	1.3	42
94	Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2627-2631.	1.3	4
95	Antiretroviral-naïve and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 566-572.	1.3	8
96	Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. <i>Mucosal Immunology</i> , 2015, 8, 127-140.	2.7	63
97	Immunologic and Virologic Progression in HIV Controllers: The Role of Viral Blips and Immune Activation in the ANRS CO21 CODEX Study. <i>PLoS ONE</i> , 2015, 10, e0131922.	1.1	50
98	Both HLA-B*57 and Plasma HIV RNA Levels Contribute to the HIV-Specific CD8 ⁺ T Cell Response in HIV Controllers. <i>Journal of Virology</i> , 2014, 88, 176-187.	1.5	39
99	Quantification of Total HIV1-DNA in Peripheral Blood Mononuclear Cells. <i>Methods in Molecular Biology</i> , 2014, 1087, 261-270.	0.4	26
100	Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4+ T cells from elite controllers. <i>Aids</i> , 2014, 28, 1567-1577.	1.0	30
101	Genotypic resistance profiles of HIV-2-treated patients in West Africa. <i>Aids</i> , 2014, 28, 1161-1169.	1.0	43
102	HIV-1 DNA concentrations and evolution among African HIV-1-infected children under antiretroviral treatment (ANRS 1244/1278). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3047-3050.	1.3	4
103	Naïve T Lymphocytes and Recent Thymic Emigrants Are Associated With HIV-1 Disease History in French Adolescents and Young Adults Infected in the Perinatal Period: The ANRS-EP38-IMMIP Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 573-587.	2.9	17
104	New Sensitive One-Step Real-Time Duplex PCR Method for Group A and B HIV-2 RNA Load. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3017-3022.	1.8	23
105	The Kidney as a Reservoir for HIV-1 after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 407-419.	3.0	121
106	Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers. <i>Transplantation Proceedings</i> , 2013, 45, 1603-1607.	0.3	43
107	Congenital Cytomegalovirus Is the Second Most Frequent Cause of Bilateral Hearing Loss in Young French Children. <i>Journal of Pediatrics</i> , 2013, 162, 593-599.	0.9	31
108	Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. <i>PLoS Pathogens</i> , 2013, 9, e1003211.	2.1	879

#	ARTICLE	IF	CITATIONS
109	Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1169-1178.	1.3	208
110	Increasing HIV-1 Non-B Subtype Primary Infections in Patients in France and Effect of HIV Subtypes on Virological and Immunological Responses to Combined Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2013, 56, 880-887.	2.9	55
111	Long-Term HIV-1 Virologic Control in Patients on a Dual NRTI Regimen. <i>HIV Clinical Trials</i> , 2013, 14, 120-126.	2.0	5
112	Congenital Cytomegalovirus Is the Second Most Frequent Cause of Bilateral Hearing Loss in Young French Children. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 501-503.	0.2	0
113	A Single HIV-1 Cluster and a Skewed Immune Homeostasis Drive the Early Spread of HIV among Resting CD4+ Cell Subsets within One Month Post-Infection. <i>PLoS ONE</i> , 2013, 8, e64219.	1.1	63
114	HIV-DNA in the Genital Tract of Women on Long-Term Effective Therapy Is Associated to Residual Viremia and Previous AIDS-Defining Illnesses. <i>PLoS ONE</i> , 2013, 8, e69686.	1.1	8
115	Immune responses and latent tissue reservoirs during the course of HIV-1 infection. <i>Virologie</i> , 2013, 17, 157-168.	0.1	0
116	Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study. <i>Clinical Infectious Diseases</i> , 2012, 55, 291-300.	2.9	209
117	Relationships Between HIV Disease History and Blood HIV-1 DNA Load in Perinatally Infected Adolescents and Young Adults: The ANRS-EP38-IMMIP Study. <i>Journal of Infectious Diseases</i> , 2012, 205, 1520-1528.	1.9	26
118	Immune Responses Driven by Protective Human Leukocyte Antigen Alleles From Long-term Nonprogressors Are Associated With Low HIV Reservoir in Central Memory CD4 T Cells. <i>Clinical Infectious Diseases</i> , 2012, 54, 1495-1503.	2.9	110
119	Prevalence and Clinical Impact of Norovirus Fecal Shedding in Children with Inherited Immune Deficiencies. <i>Journal of Infectious Diseases</i> , 2012, 206, 1269-1274.	1.9	65
120	CCR5 antagonists. <i>Aids</i> , 2012, 26, 1673-1677.	1.0	11
121	Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV. <i>Aids</i> , 2012, 26, 711-720.	1.0	20
122	CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory. <i>PLoS ONE</i> , 2011, 6, e18726.	1.1	52
123	Impact of Norovirus/Sapovirus-Related Diarrhea in Renal Transplant Recipients Hospitalized for Diarrhea. <i>Transplantation</i> , 2011, 92, 61-69.	0.5	130
124	Lopinavir/Ritonavir-based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Naïve Children. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 684-688.	1.1	18
125	Elite controllers as a model of functional cure. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 181-187.	1.5	108
126	Greater diversity of HIV DNA variants in the rectum compared to variants in the blood in patients without HAART. <i>Journal of Medical Virology</i> , 2011, 83, 1499-1507.	2.5	23

#	ARTICLE	IF	CITATIONS
127	Prospective Identification of Congenital Cytomegalovirus Infection in Newborns Using Real-Time Polymerase Chain Reaction Assays in Dried Blood Spots. <i>Clinical Infectious Diseases</i> , 2011, 52, 575-581.	2.9	66
128	Adenoviral Infection Presenting as an Isolated Central Nervous System Disease without Detectable Viremia in Two Children after Stem Cell Transplantation. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2361-2364.	1.8	23
129	Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. <i>Aids</i> , 2010, 24, 1598-1601.	1.0	179
130	Evaluation of an Upgraded Version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test for HIV-1 Load Quantification. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1413-1416.	1.8	47
131	Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123-ETOILE). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2212-2214.	1.3	17
132	Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1005-1007.	1.3	21
133	Short Communication: Evidence of HIV Type 1 Complex and Second Generation Recombinant Strains Among Patients Infected in 1997-2007 in France: ANRS CO06 PRIMO Cohort. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 645-651.	0.5	19
134	Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. <i>Journal of Clinical Investigation</i> , 2009, 119, 997-1007.	3.9	288
135	Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 433-434.	1.3	15
136	Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses. <i>Journal of Immunology</i> , 2009, 182, 7828-7837.	0.4	183
137	LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). <i>Journal of Medical Virology</i> , 2009, 81, 217-223.	2.5	195
138	S03-04 OA. Transitional and central memory CD4 T cells are highly infected in long term non progressors and elite controllers. <i>Retrovirology</i> , 2009, 6, .	0.9	1
139	Early Control of HIV-1 Infection in Long-Term Nonprogressors Followed Since Diagnosis in the ANRS SEROCO/HEMOCO Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 19-26.	0.9	33
140	Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection. <i>PLoS ONE</i> , 2009, 4, e6093.	1.1	222
141	HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. <i>Journal of Clinical Virology</i> , 2008, 42, 399-404.	1.6	55
142	HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. <i>Aids</i> , 2008, 22, 1880-1882.	1.0	55
143	Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study. <i>PLoS ONE</i> , 2008, 3, e3907.	1.1	171
144	Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART. <i>Aids</i> , 2007, 21, 776-777.	1.0	32

#	ARTICLE	IF	CITATIONS
145	476 Reasons for the lack of anti-HBc antibody detection in hepatitis B virus infected patients. Journal of Hepatology, 2006, 44, S177.	1.8	0
146	Immune Suppression as the Etiology of Failure To Detect Anti-HBc Antibodies in Patients with Chronic Hepatitis B Virus Infection. Journal of Clinical Microbiology, 2006, 44, 2250-2253.	1.8	36
147	Use of Genotypic Identification by sodA Sequencing in a Prospective Study To Examine the Distribution of Coagulase-Negative Staphylococcus Species among Strains Recovered during Septic Orthopedic Surgery and Evaluate Their Significance. Journal of Clinical Microbiology, 2005, 43, 2952-2954.	1.8	57
148	Use of sodA sequencing for the identification of clinical isolates of coagulase-negative staphylococci. Clinical Microbiology and Infection, 2004, 10, 939-942.	2.8	28